1-5 of 5
Sarah Bailly
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Verlen, “Very Elderly Rituximab Associated to Lenalidomide - Tafasitamab Combination in Frontline DLBCL Patients”, a Phase II Open-Label Study Evaluating Efficacy of Lenalinomide and Tafasitamab Combination Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older from the Lysa Group

Benoit Tessoulin, Julien Depaus, Pierre Feugier, Ludovic Fouillet, Julie Abraham, Sandy Amorin, Fabrice Jardin, Franck Morschhauser, Catherine Thieblemont, François-Xavier Gros, Bertrand Joly, Hacene Zerazhi, Sophie Bernard, Adrien Chauchet, Stéphane Vigouroux, Christophe Bonnet, Sarah Bailly, Steven Le Gouill
Journal: Blood
Blood (2023) 142 (Supplement 1): 3094.
https://doi.org/10.1182/blood-2023-173265
Published: 2023
Journal Articles

R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers

Vincent Camus, Alina Berriolo-Riedinger, Justine Lequesne, David Tonnelet, MD, Pierre Decazes, Cédric Rossi, MD PhD, Pierre Sesques, MD, Corinne Haioun, MD PhD, Eric Durot, MD, Alexandre Willaume, Martin Gauthier, Marie-Pierre Moles, MD, Chloe Antier, Julien Lazarovici, MD, Helene Monjanel, Sophie Bernard, Magalie Tardy, Caroline Besson, MDPhD, Laure Lebras, MD, Choquet Sylvain, Katell Le Du, MD, Christophe Bonnet, MD, Sarah Bailly, MD, Damaj Gandhi Laurent, MD PhD, Kamel Laribi, MD, Herve Maisonneuve, MD, Roch Houot, MDPhD, Adrien Chauchet, MD, Fabrice Jardin, MD PhD, Stephanie Becker, MD, Herve Tilly, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-136600
Published: 2020
Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Radhakrishnan Ramchandren, MD, Peter Johnson, MDFRCP, Nilanjan Ghosh, MD PhD, Jia Ruan, MD PhD, Kirit M. Ardeshna, MA, MD FRCP, FRCPath, Roderick Johnson, MD, Gregor Verhoef, MD PhD, David Cunningham, MD FRCP, FMedSci, Sven de Vos, MD PhD, Shireen Kassam, MD, Luis Fayad, MD, John Radford, Sarah Bailly, MD, Fritz Offner, MD, David Morgan, MD, Javier Munoz, MD, Jerry Ping, PhD, Kevin Kwei, PhD, Karl Eckert, BA, Jutta K. Neuenburg, MD PhD, Andre Goy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 761.
https://doi.org/10.1182/blood-2019-121521
Published: 2019
Journal Articles

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Cédric Rossi, MD PhD, Marc André, Clémentine Joubert, PhD, Catherine Fortpied, Pauline Brice, Bénédicte Deau-Fisher, MD, Herve Ghesquieres, MD PhD, Luc Mathieu Fornecker, MD PhD, Anne-Claire Gac, MD, Julien Lazarovici, Aspasia Stamatoullas, MD, John Raemakers, Massimo Federico, MD, Marie Maerevoet, MD, Sarah Bailly, MD, Salim Kanoun, MD, Michel Meignan, Anne Ségolène Cottereau, Rene-Olivier Casasnovas, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 128.
https://doi.org/10.1182/blood-2019-125976
Published: 2019
Journal Articles

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Radhakrishnan Ramchandren, MD, Peter Johnson, MD, Nilanjan Ghosh, MD PhD, Jia Ruan, MD PhD, Kirit M. Ardeshna, MA MDFRCP FRCPath, Roderick Johnson, MD, Gregor Verhoef, MD PhD, David Cunningham, Sven de Vos, Shireen Kassam, MD, Luis Fayad, MD, John Radford, MD FRCP, Sarah Bailly, MD, Fritz Offner, MD, David Morgan, MD, Javier Munoz, MD, Jerry Ping, PhD, Melannie Co, MD BSMedTech, BSN, Jutta K. Neuenburg, MD PhD, Andre Goy, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 402.
https://doi.org/10.1182/blood-2018-99-111163
Published: 2018